Polyphor achieves ahead of schedule first milestone from Wellcome Trust for the development of novel antibiotics against Gram-negative multidrug – resistant pathogens

July 18, 2017
Polyphor Ltd

July 18, 2017 - Polyphor Ltd. announced today that it has made significant progress in the discovery and early development of novel broad-spectrum, outer membrane protein targeting Gram-negative antibiotics (OMPTA). This has triggered, ahead of schedule, a first 0.6 mCHF milestone payment from the Wellcome Trust under a Seeding Drug Discovery Award of total up to 2.3 mCHF granted in February 2017. The company already received an upfront payment of 0.7 mCHF.

Press Release available here: